---
title: "Polygenic and familial influences on antidepressant continuation, switching, discontinuation and a"
id: "medrxiv-13-polygenic-and-familial-contributions-to-antidepressant-continuation-switching"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-13-polygenic-and-familial-contributions-to-antidepressant-continuation-switching"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.14.26360458v1?rss=1"
published_at: "2026-08-17T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Polygenic and familial influences on antidepressant continuation, switching, discontinuation and a
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-13-polygenic-and-familial-contributions-to-antidepressant-continuation-switching
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.14.26360458v1?rss=1)
- **Published At:** 2026-08-17T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This preprint analysed antidepressant treatment patterns in two large cohorts: **All of Us (AoU, n=98,357)** and Pharmlines (Lifelines linked to IADB.nl, n=12,884). The sample included participants with at least one antidepressant monotherapy episode ≥28 days. - The study compared four treatment outcomes: **continuation**, **switching**, **discontinuation**, and **augmentation** (addition of atypical antipsychotic or lithium), and related these to polygenic scores (PGS) for psychiatric disorders and to familial aggregation. - Among individuals with recorded major depressive disorder, **switching** (but not discontinuation) correlated with co-occurring anxiety, higher depression symptom counts, and stress-related measures in both cohorts, suggesting clinical severity contributes to switching. - A **depression PGS** was associated with switching in AoU (OR 1.16 per SD, 95% CI 1.12–1.20) and showed a concordant nominal association in Pharmlines (OR 1.11, 95% CI 1.01–1.22). - In AoU, depression PGS increased stepwise across outcomes from continuation to switching to augmentation (per-step OR 1.18, 95% CI 1.15–1.21), indicating a graded relationship between genetic liability for depression and more intensive treatment modifications. - **Schizophrenia** and **bipolar disorder PGS** were selectively associated with **augmentation**, implying cross-disorder genetic complexity among those who receive augmentation. - No PGS demonstrated **drug-class-specific** associations with switching, suggesting polygenic liability did not map to non-response specific to an antidepressant class in this analysis. - Familial aggregation (in Pharmlines) was present for **continuation**, including for SSRI and SNRI continuation, but familial aggregation was not detectable for switching or discontinuation, indicating sustained, switch-free continuation clusters in families. - The authors interpret switching as partly indexing **depression severity** rather than purely drug-specific non-response, while augmentation reflects broader psychiatric comorbidity or cross-disorder complexity. Familial effects were confined to stable continuation. - The work is a preprint and not peer reviewed. Ethical approvals were reported (All of Us Research Program IRB; METc 2007/152 for the University Medical Center Groningen). Data are not available upon request, and funders are listed in the source.
## Clinical Analysis & Structured Key Points
Polygenic and familial contributions to antidepressant continuation, switching, discontinuation and augmentation in the All of Us and Pharmlines cohorts | medRxiv Skip to main content Polygenic and familial contributions to antidepressant continuation, switching, discontinuation and augmentation in the All of Us and Pharmlines cohorts View ORCID Profile Alicia Walker , Xiaotong Wang , Jens Bos , Tian Lin , Frank Klont , Ilja Nolte , Harold Snieder , Roeland Broekema , Peter M. Visscher , Anjali K. Henders , Catharina Hartman , Hanna M. van Loo , Maxime Taquet , Eelko Hak , View ORCID Profile Naomi R. Wray doi: https://doi.org/10.64898/2026.08.14.26360458 Alicia Walker 1 University of Oxford; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Alicia Walker Xiaotong Wang 1 University of Oxford; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jens Bos 2 University of Groningen; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tian Lin 3 The University of Queensland Find this author on Google Scholar Find this author on PubMed Search for this author on this site Frank Klont 2 University of Groningen; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ilja Nolte 2 University of Groningen; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Harold Snieder 2 University of Groningen; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Roeland Broekema 1 University of Oxford; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Peter M. Visscher 1 University of Oxford; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Anjali K. Henders 1 University of Oxford; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Catharina Hartman 2 University of Groningen; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hanna M. van Loo 2 University of Groningen; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Maxime Taquet 1 University of Oxford; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Eelko Hak 2 University of Groningen; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Naomi R. Wray 1 University of Oxford; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Naomi R. Wray For correspondence: naomi.wray{at}psych.ox.ac.uk Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Predicting antidepressant response remains a major challenge, and it is unclear whether reported polygenic associations reflect drug-specific non-response or a broader propensity for treatment modification. We analysed participants with at least one antidepressant monotherapy episode of ≥28 days in the All of Us (AoU; n=98,357) and Pharmlines (Lifelines linked to IADB.nl; n=12,884) cohorts, comparing continuation with switching, discontinuation and augmentation (atypical antipsychotic or lithium) in relation to polygenic scores (PGS). Among individuals with recorded major depressive disorder, switching, but not discontinuation, was associated with anxiety, higher depression symptom count and stress-related measures in both cohorts. Depression PGS was associated with switching in AoU (OR=1.16 per SD, 95% CI 1.12–1.20), with a concordant nominally significant estimate in Pharmlines (OR=1.11, 1.01–1.22). In AoU, depression PGS increased progressively from continuation to switching to augmentation (per-step OR=1.18, 1.15–1.21), whereas schizophrenia and bipolar disorder PGS were selectively associated with augmentation. No PGS showed drug-class-specific associations with switching. Familial aggregation in Pharmlines was detectable for continuation, including SSRI and SNRI continuation, but not for switching or discontinuation. Antidepressant switching therefore partly indexes depression severity rather than drug-specific non-response alone, whereas augmentation captures cross-disorder psychiatric complexity, and familial aggregation was confined to sustained, switch-free continuation. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The All of Us Research Program Institutional Review Board gave ethical approval for this work. The Medical Ethical Committee of the University Medical Center Groningen (METc 2007/152) gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Data is not available upon request. Funder Information Declared Dutch Ministry of Health, Welfare and Sport Dutch Ministry of Economic Affairs University Medical Center Groningen (UMCG), University of Groningen and the Provinces in the North of the Netherlands (Drenthe, Friesland, Groningen) Michael Davys Trust, University of Oxford National Health and Medical Research Council , 1173790 and 1113400 Wellcome Trust , 226770/Z/22/Z Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted August 17, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Polygenic and familial contributions to antidepressant continuation, switching, discontinuation and augmentation in the All of Us and Pharmlines cohorts Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Polygenic and familial contributions to antidepressant continuation, switching, discontinuation and augmentation in the All of Us and Pharmlines cohorts Alicia Walker , Xiaotong Wang , Jens Bos , Tian Lin , Frank Klont , Ilja Nolte , Harold Snieder , Roeland Broekema , Peter M. Visscher , Anjali K. Henders , Catharina Hartman , Hanna M. van Loo , Maxime Taquet , Eelko Hak , Naomi R. Wray medRxiv 2026.08.14.26360458; doi: https://doi.org/10.64898/2026.08.14.26360458 Share This Article: Copy Citation Tools Polygenic and familial contributions to antidepressant continuation, switching, discontinuation and augmentation in the All of Us and Pharmlines cohorts Alicia Walker , Xiaotong Wang , Jens Bos , Tian Lin , Frank Klont , Ilja Nolte , Harold Snieder , Roeland Broekema , Peter M. Visscher , Anjali K. Henders , Catharina Hartman , Hanna M. van Loo , Maxime Taquet , Eelko Hak , Naomi R. Wray medRxiv 2026.08.14.26360458; doi: https://doi.org/10.64898/2026.08.14.26360458 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Genetic and Genomic Medicine Subject Areas All Articles Addiction Medicine (605) Allergy and Immunology (891) Anesthesia (324) Cardiovascular Medicine (4719) Dentistry and Oral Medicine (471) Dermatology (403) Emergency Medicine (633) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1601) Epidemiology (15730) Forensic Medicine (32) Gastroenterology (1189) Genetic and Genomic Medicine (6925) Geriatric Medicine (723) Health Economics (1043) Health Informatics (4912) Health Policy (1416) Health Systems and Quality Improvement (1717) Hematology (571) HIV/AIDS (1319) Infectious Diseases (except HIV/AIDS) (16193) Intensive Care and Critical Care Medicine (1152) Medical Education (657) Medical Ethics (150) Nephrology (713) Neurology (7101) Nursing (358) Nutrition (1064) Obstetrics and Gynecology (1214) Occupational and Environmental Health (990) Oncology (3539) Ophthalmology (1024) Orthopedics (384) Otolaryngology (440) Pain Medicine (461) Palliative Medicine (138) Pathology (700) Pediatrics (1761) Pharmacology and Therapeutics (728) Primary Care Research (754) Psychiatry and Clinical Psychology (5775) Public and Global Health (9607) Radiology and Imaging (2355) Rehabilitation Medicine and Physical Therapy (1415) Respiratory Medicine (1231) Rheumatology (631) Sexual and Reproductive Health (759) Sports Medicine (571) Surgery (755) Toxicology (106) Transplantation (300) Urology (282)
## Related Clinical Research

- [Heterogeneity in Excess Mortality by Diagnosis, Care Setting, and Substance Use in Finland Cohort](https://medichelpline.com/clinical-feed/medrxiv-17-heterogeneity-in-excess-mortality-across-mental-behavioural-and.md)
- [End-of-life symptom prevalence and drivers among hospital decedents in South Korea](https://medichelpline.com/clinical-feed/plos-one-3-prevalence-and-influencing-factors-of-end-of-life-symptoms-among-hospital.md)
- [Digital eMPower program reduces anxiety and depression in adults with chronic conditions: randomiz](https://medichelpline.com/clinical-feed/plos-medicine-0-effect-of-a-digital-intervention-on-mental-health-symptoms-in-adults-with.md)
- [Psychometric evaluation of the CISS-SF: validity, reliability, and factor structure](https://medichelpline.com/clinical-feed/plos-one-14-psychometric-properties-of-a-short-form-for-the-coping-inventory-for-stressful.md)
- [Nurse Practitioner Trainees Face Clinical Mentor Shortage and Preceptor Challenges](https://medichelpline.com/clinical-feed/stat-news-3-nurse-practitioner-trainees-find-themselves-stymied-by-shortage-of-clinical.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.